First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

• Main Authors: Michael Boyiadzis (Author), Pinkal Desai (Author), Nikki Daskalakis (Author), William Donnellan (Author), Lucille Ferrante (Author), Jenna D. Goldberg (Author), Michael R. Grunwald (Author), Christina Guttke (Author), Xiang Li (Author), Jose Antonio Perez‐Simon (Author), Olga Salamero (Author), Trevor Tucker (Author), Xiaoying Xu (Author), Jay Yang (Author), Naveen Pemmaraju (Author), Juan Manuel Alonso‐Dominguez (Author)
• Format: Book
• Published: Wiley, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with relapsed or refractory acute myeloid leukemia. Intraven...